{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Gastroesophageal+Junction&page=13", "query": { "condition": "Adenocarcinoma Gastroesophageal Junction", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 343, "total_pages": 35, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Gastroesophageal+Junction&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Gastroesophageal+Junction&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T10:08:29.146Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04615013", "title": "NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Esophagus Adenocarcinoma", "Clinical Stage II Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage II Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8", "Thoracic Esophagus Adenocarcinoma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Hafnium Oxide-containing Nanoparticles NBTXR3", "type": "OTHER" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2020-11-23", "completion_date": "2027-10-31", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-15T10:08:29.146Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04615013" }, { "nct_id": "NCT00711243", "title": "Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 59, "start_date": "2005-04-20", "completion_date": "2011-02-25", "has_results": true, "last_update_posted_date": "2019-02-26", "last_synced_at": "2026-10-15T10:08:29.146Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00711243" }, { "nct_id": "NCT05709574", "title": "Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Tadalafil 20 MG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2023-04-20", "completion_date": "2026-10-30", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-15T10:08:29.146Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05709574" }, { "nct_id": "NCT00891878", "title": "Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Gastroesophageal Junction", "Esophageal Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "sunitinib malate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2009-08", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2018-07-24", "last_synced_at": "2026-10-15T10:08:29.146Z", "location_count": 182, "location_summary": "Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 112 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Bloomington", "state": "Illinois" }, { "city": "Bloomington", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00891878" }, { "nct_id": "NCT05891171", "title": "Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Advanced Malignancies", "Bladder Cancer", "Cervical Cancer", "Esophageal Cancer", "Gastric Cancer", "Gastroesophageal-junction Cancer (GEJ)", "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Non-Small Cell Lung Cancer (NSCLC)", "Ovarian Cancer", "Renal Cell Carcinoma (RCC)", "Triple Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "AB598", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2023-10-13", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-15T10:08:29.146Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Lake City, Florida + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Lake City", "state": "Florida" }, { "city": "Hinsdale", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05891171" }, { "nct_id": "NCT03735290", "title": "A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Squamous Cell of Head and Neck", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "ilixadencel", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Mendus", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2019-01-14", "completion_date": "2021-12-03", "has_results": false, "last_update_posted_date": "2022-03-16", "last_synced_at": "2026-10-15T10:08:29.146Z", "location_count": 5, "location_summary": "Coral Gables, Florida • Iowa City, Iowa • Louisville, Kentucky + 2 more", "locations": [ { "city": "Coral Gables", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03735290" }, { "nct_id": "NCT02625610", "title": "Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Best supportive care", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 499, "start_date": "2015-12-24", "completion_date": "2021-06-03", "has_results": true, "last_update_posted_date": "2022-06-09", "last_synced_at": "2026-10-15T10:08:29.146Z", "location_count": 35, "location_summary": "Bakersfield, California • Fullerton, California • Los Angeles, California + 31 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02625610" }, { "nct_id": "NCT00381706", "title": "Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "ECF", "type": "DRUG" }, { "name": "IC", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 245, "start_date": "2006-09-15", "completion_date": "2014-10-15", "has_results": true, "last_update_posted_date": "2021-09-29", "last_synced_at": "2026-10-15T10:08:29.146Z", "location_count": 227, "location_summary": "Norwalk, Connecticut • Lewes, Delaware • Newark, Delaware + 158 more", "locations": [ { "city": "Norwalk", "state": "Connecticut" }, { "city": "Lewes", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Aurora", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00381706" }, { "nct_id": "NCT05041153", "title": "Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Advanced Gastric Adenocarcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVB Gastric Cancer AJCC v8", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage III Gastric Cancer AJCC v8", "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Gastric Cancer AJCC v8", "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Gastric Cancer AJCC v8", "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIC Gastric Cancer AJCC v8", "Pathologic Stage IV Gastric Cancer AJCC v8", "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8", "Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8", "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Unresectable Gastric Adenocarcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2022-02-14", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-15T10:08:29.146Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05041153" }, { "nct_id": "NCT03604991", "title": "Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Clinical Stage II Esophageal Adenocarcinoma AJCC v8", "Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Esophageal Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 278, "start_date": "2019-05-03", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-15T10:08:29.146Z", "location_count": 488, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 341 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03604991" } ] }